KScan

KScan phosphoproteomics platform

KScan, the phosphoproteomics platform developed by Kinomica’s founders, has the potential to predict patient responses to targeted therapies with greater accuracy than currently possible.

KScan directly measures intracellular kinase and cell-signalling pathway activity in cells and tissues, and combines the phosphoproteomics readout with innovative computational (including machine-learning) algorithms and high-quality data to reveal drug molecular efficacy, mechanisms of action and therapeutic resistance; identify and validate new biomarkers; inform diagnostic decision-making; and identify novel and/or alternative drug targets and therapies.

scientist in a white coat examing informtion on a clip board scientist stood in a lab wearing a white coat examining data on a clip board
KScan our phosphoproteomics platform KScan bioinformatics and phosphoproteomics machine in the lab

The KScan offering can be tailored to provide a range of services to meet specific customer needs and is being developed further as a companion diagnostic technology to guide physicians in the selection of effective treatment for each individual patient, facilitation enhanced precision medicine.

Technologies

Find out more about Kinomica’s powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods

LC/MS/MS mass spectrometer
scientist in a white coat looking at a laptop male scientist wearing a white coat looking at a laptop screen

Kinomica News

Learn more about Kinomica, our team and our technology through our in-depth blog content. We’ll also let you know what events we are attending as well.

Talk to our Experts

To find out more about the technology behind Kinomica’s advanced bioinformatics and phosphoproteomics analytical methods, talk to our experts.

Contact Us

If you have any questions or need any further information, then please contact the Kinomica team – we are more than happy to help.

“Our technology and analysis capabilities will mean that patients can be matched to the correct drugs reducing time spent on ineffective medicines and increasing lifespans and quality of life”

Jane Theaker, Kinomica CEO